NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

多發性硬化症:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Multiple Sclerosis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024231
出版日期 內容資訊 英文 272 Pages
商品交期: 3-5個工作天內
價格
多發性硬化症:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Multiple Sclerosis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 272 Pages
簡介

本報告提供多發性硬化症市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 多發性硬化症的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 多發性硬化症的交易趨勢

第7章 多發性硬化症的開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH504

GervanoRA's pipeline analysis and opportunity assessment report "Multiple Sclerosis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Multiple Sclerosis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Multiple Sclerosis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Multiple Sclerosis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Multiple Sclerosis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Multiple Sclerosis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Multiple Sclerosis Market (2020) and the Forecasted Multiple Sclerosis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Multiple Sclerosis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Multiple Sclerosis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Multiple Sclerosis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: MULTIPLE SCLEROSIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF MULTIPLE SCLEROSIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF MULTIPLE SCLEROSIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: GLOBAL MS EPIDEMIOLOGY (2020), FORECAST (2021-2030)
  • TABLE 03: MAJOR MERGERS AND ACQUISITIONS IN MS THERAPEUTIC AREA
  • TABLE 04: MAJOR COLLABORATIVE AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 05: MAJOR LICENSING AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 06: MAJOR FINANCING AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 07: MAJOR TERMINATION AND SETTLEMENT AGREEMENTS IN MS THERAPEUTIC AREA
  • TABLE 08: USFDA APPROVED DRUGS SINCE 2010
  • TABLE 09: EMA OR EX-US DRUG APPROVALS SINCE 2010
  • TABLE 10: PHASE 3 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 11: PHASE 2 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 12: PHASE 1 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 13: PRECLINICAL MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 14: EARLY R&D MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 15: ORALLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 16: INTRAVENOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 17: SUBCUTANEOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 18: MULTIPLE SCLEROSIS PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 19: UNIVERSITY AND INSTITUTE'S PIPELINE MOLECULES FOR MS
  • TABLE 20: APPROVAL TIMELINES COMPARISON, GERVANORA ESTIMATIONS V/S ACTUAL APPROVAL

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN MULTIPLE SCLEROSIS DISEASE AREA
  • FIGURE 02: GLOBAL MS POPULATION (2020) FORECAST (2021-2030), IN MILLION
  • FIGURE 03: US MS POPULATION (2020) FORECAST (2021-2030), IN MILLION
  • FIGURE 04: OVERALL DEALS ACTIVITY IN MS THERAPEUTIC AREA SINCE 2010
  • FIGURE 05: MULTIPLE SCLEROSIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 06: MULTIPLE SCLEROSIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 07: MULTIPLE SCLEROSIS PIPELINE ANALYTICS BY COMPANY TYPE
  • FIGURE 08: UNIVERSITY MOLECULES FOR MS, BY HSD
  • FIGURE 09: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES
  • FIGURE 10: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR REGULATORY ALLOWANCES